HSCS (HeartSciences) EBIT: $-7.78 Mil (TTM As of Jan. 2026)

What is HeartSciences EBIT?

HeartSciences HSCS -1.18% 41 EBIT is $-7.78 Mil as of Jan. 2026. GuruFocus rates HSCS with a GF Score™ of 41/100 and a GF Value™ of $2.61 (Modestly Overvalued). The stock has 7 warning signs investors should review.

HeartSciences's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2026 was $-1.92 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2026 was $-7.78 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. HeartSciences's annualized ROC % for the quarter that ended in Jan. 2026 was -170.88%. HeartSciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was -672.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. HeartSciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was -76.66%.

HeartSciences (NAS:HSCS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

HeartSciences's annualized ROC % for the quarter that ended in Jan. 2026 is calculated as:

	ROC % (Q: Jan. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2025 )	+	Invested Capital (Q: Jan. 2026 ))	/ count )
=	-7.716 * ( 1 - 0% )	/	( (3.256	+	5.775)	/ 2 )
=	-7.716	/	4.5155
=	-170.88 %

where

	Invested Capital		(Q: Oct. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.996	-	0.789	-	( 1.951	-	max(0, 1.566	-	3.793	+	1.951	))
=	3.256

	Invested Capital		(Q: Jan. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.555	-	0.95	-	( 3.397	-	max(0, 4.269	-	5.099	+	3.397	))
=	5.775

Note: The Operating Income data used here is four times the quarterly (Jan. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

HeartSciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jan. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Oct. 2025		Q: Jan. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.696	/	( ( (0.375 + max(0.905, 0))	+	(0.341 + max(0.667, 0)) )	/	2 )
=	-7.696	/	( ( 1.28	+	1.008 )	/	2 )
=	-7.696	/	1.144
=	-672.73 %

where Working Capital is:

	Working Capital		(Q: Oct. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.657	+	1.185)	-	(0.789	+	0	+	0.148)
=	0.905

	Working Capital		(Q: Jan. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.657	+	1.045)	-	(0.95	+	0	+	0.085)
=	0.667

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

HeartSciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jan. 2026 )
	=	-7.779	/	10.147
	=	-76.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeartSciences EBIT Related Terms

HeartSciences EBIT Historical Data

* Premium members only.

The historical data trend for HeartSciences's EBIT can be seen below:

HeartSciences EBIT Chart

HeartSciences Annual Data

Trend

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

EBIT

Get a 7-Day Free Trial

-2.32

-4.46

-6.11

-6.25

-8.27

HeartSciences Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26
EBIT	Get a 7-Day Free Trial															-2.36	-1.91	-1.87	-2.07	-1.92

HSCS vs FEED, ITOC, LUDG: EBIT Comparison

For the Medical Devices subindustry, HeartSciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HeartSciences EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HeartSciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HeartSciences's EV-to-EBIT falls into.

Save Embed

41GF Score

HeartSciences Inc HSCS

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

HeartSciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.78 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-7.78 Mil mean?

HeartSciences (HSCS) has a EBIT of $-7.78 Mil as of Jan. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on HeartSciences.

Is HeartSciences' EBIT too high?

HeartSciences' current EBIT is $-7.78 Mil. Overall, HeartSciences has a GF Score™ of 41/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does HeartSciences' EBIT compare to FEED and ITOC?

HeartSciences' EBIT of $-7.78 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on HeartSciences. HeartSciences's current EBIT is $-7.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is HeartSciences stock overvalued right now?

Based on GuruFocus' analysis, HeartSciences (HSCS) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.61, compared to a current price of $2.90 — trading 11.1% above its estimated fair value. The current EBIT is $-7.78 Mil. HeartSciences' overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For HeartSciences (HSCS), the current EBIT is $-7.78 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $2.90 is trading 11.1% above its estimated GF Value™ of $2.61. GuruFocus considers HeartSciences to be Modestly Overvalued.

Key valuation signals for HSCS:

EBIT: $-7.78 Mil
GF Value™: $2.61 vs. price of $2.90 (11.1% above fair value)
GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeartSciences Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies FEED ITOC LUDG XAIR ADMT AMIX INBS RBOT BTCY RMSL ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092

Website https://www.heartsciences.com

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

41GF Score

Get the complete analysis for HSCS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.90

Price

$2.61

GF Value

View HSCS Analysis

See EBIT data for all stocks →